CD47 Research at Stanford

Options
2

Comments

  • JohnSmith
    JohnSmith Member Posts: 651
    edited February 2016

    That was written in July 2013 and much more has been elucidated since then. The emergence of numerous players, each creating their own Anti-CD47 approach, will ensure that one of them, if not all, will be successful. Like the author wrote, most believe that Anti-CD47 will be best in "combination therapy" settings. As a monotherapy (single agent), it probably won't be a smashing success, but who knows? We'll find out that answer within the next 6-9 months. As we all know, the purpose of the Phase 1 trials is to determine safety and the proper dosage. Anything beyond that is 'icing on the cake'.

    Here's a great article released today about Toronto-based Trillium Therapeutics and their Anti-CD47 mAb. It's written by a PhD post-doc researcher who works in cancer research.
    "Trillium Therapeutics: A pure-play on CD47 as an immuno-oncology target"

    Also, there's a Facebook group called: "People for CD47 Cancer Cure" which discusses many of these concepts and provides updates on the clinical trials. Feel free to join the group and ask questions. The admin, a guy named Milan, is quite helpful at answering questions.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited November 2015

    I think that many here will want to sign this petition: http://www.alltrials.net/petition/

    I think many stage IV women know about a stem cell therapy that was used many years ago and then was discontinued, I know someone on BCO posted the video contained in the following link but the interesting thing is the last paragraph of this link in which it is stated that Stanford is doing a clinical trial of this and if you are interested in it they have an email address for you to contact http://stemcell.stanford.edu/video/patientvideo.html

    Both of these links were found on the fb book page that JS included above.

  • JohnSmith
    JohnSmith Member Posts: 651
    edited November 2015

    ML,
    I'm not familiar with the petition issue. Perhaps a new thread could be started to discuss this?

    Now, in terms of the high-dose chemo with purified stem cell therapy.
    There's no question that the late 1990's phase I/II breast cancer clinical trial of High-Dose Chemo with rescue by autologous mobilized peripheral blood (MPB) is intriguing.
    I think this might be the original 1996 trial link from clinicaltrials.gov
    This 2012 Abstract discusses the trial results. Updates to this trial have also been discussed in Dr. Weissman's presentations, such as this more recent UCLA video from June 2015: "Why Aren't We Translating Discoveries When We Can? Some Case Studies" (~9 minutes in)

    I'm told that larger RCT's were done and failed. I never researched those trials and have no other details though.

    I'm also told the biggest issue with this approach is two words: "Werner Bezwoda". He's the South African stem cell scientist who fraudulently falsified his breast cancer purified stem cell research during the 1990's. He was fired in March 2000. Here's the wiki on the history.
    It was such a scandal that it destroyed any chance that this therapy would be used by the current generation of oncologists. Here's an editorial written in 2000, shortly after the scandal was revealed, which discusses why this hurt the breast cancer community.
    "Why Big Lies Matter: Lessons From the Bezwoda Affair"

    It appears your video of Stage 4 Stanford survivor, E. Perez, is from January 2012.
    I'd suggest emailing Dr. Judith Shizuru at Stanford (jshizuru@stanford) and ask if, and when, these trials will be re-launched.
    I do think this is a topic that warrants a discussion, but it would be wise to start a new thread, since this has little to do with the ongoing CD47 effort. ;)

  • MusicLover
    MusicLover Member Posts: 4,225
    edited November 2015

    I may create the new threads but wanted to mention them here since I would have never found them without investigating the fb book page you provided a link to, I had gone on there awhile ago but there wasn't much info at that time. Thank you again for keeping us updated. Some of the info is over my head but the bottom line is everyone is still waiting on results of the phase I clinical trial.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited November 2015

    Extremely encouraging article. But is this too good to be true ?

    http://blog.cirm.ca.gov/2015/10/01/three-teams-emp...


  • MusicLover
    MusicLover Member Posts: 4,225
    edited November 2015

    This is very good news. I think it is the first time that I have seen the dendritic cell therapy discussed like this. There is a woman named Shannon Knight who used it for stage IV bc and was successful, she did a number of other things also but this may have been the key thing that helped her, I think so anyway. You can do a search on her on the web if you want to read about her story.

    I am amazed though that the man with stage IV melanoma was treated successfully so long ago, over 10 years ago, but yet everything takes such a long time to become mainstream?

    Thank you for posting this.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited November 2015

    Clinical trial often takes very long time. The highly encouraging fact is that, it has made its way to Phase 3 clinical trial.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited November 2015

    That's for Melanoma correct? The one for breast cancer is in phase I so maybe in 10 years...(which won't be soon enough for me.) I hope I am wrong.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited November 2015

    Why don't you reach out to them directly and find out how they can help you ?

  • MusicLover
    MusicLover Member Posts: 4,225
    edited November 2015

    Thank you, I did contact them awhile ago. Maybe I can get into a phase II clinical trial, if phase I goes well. I think that is the best I can hope ofr currently. Thank you again.

  • JohnSmith
    JohnSmith Member Posts: 651
    edited December 2015

    News was just published (here and here) that Oxford University, in association with the Stanford Institute for Stem Cell Biology and Regenerative Medicine, has begun a Phase 1 Clinical Trial of the Anti-CD47 therapy against Acute Myeloid Leukemia (AML).

  • Cure-ious
    Cure-ious Member Posts: 2,626
    edited December 2015

    John: Because Phase I looks at various solid tumors, what would Phase 2 look like? Surely not CD47 treatment for a variety of metastatic cancers versus no treatment? Wouldn't it be cumbersome to compare to multiple other standards of care for different solid tumors? Maybe CD47 alone versus in combination with PD-L1? Or will they have to pick specific cancers for further testing...

  • JohnSmith
    JohnSmith Member Posts: 651
    edited December 2015

    Here's a new 4 minute easy to understand video on CD47, with focus on breast cancer, here.

    @Cure-ious. I'm not qualified to answer your questions. There's a Ovarian cancer thread on the inspire.com forum discussing CD47. There are a number of highly educated and informed patients/caretakers that might be able to answer your questions.
    Thread is here.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited December 2015

    JS, Thank you. Can you fix your first link because it is currently not working? Thanks again.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited December 2015
  • JohnSmith
    JohnSmith Member Posts: 651
    edited January 2016

    A new company called Alexo Therapeutics has emerged in the CD47 space, further validating this Immunotherapy approach.

    The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, and Irv Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1
    Alexo closed Series A funding of $36M in May 2015, which was led by venBio and joined by Lightstone Ventures, the Longevity Fund, and Stanford University. The R&D team is located in San Francisco, California.

  • JohnSmith
    JohnSmith Member Posts: 651
    edited January 2016

    This is good news.
    Stanford has been very quiet about the CD47 trials. This one minute video, released today, here, is the first clinical update I've seen. It comes from Stanford's Dr. Krampitz who has been involved in pancreatic cancer & CD47 since the pre-clinical days.
    It's not the greatest video (in terms of presentation), but the message is clear.
    Safety is good. No adverse effects among patients.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited January 2016

    JS, Thank you, that is good news.

  • letranger
    letranger Member Posts: 234
    edited January 2016

    I'm starting a clinical trial at Stanford with another drug next week so I am going to try to remember to ask the clinical onc about CD47. Thanks for keeping us updated. I am following this thread.

  • JohnSmith
    JohnSmith Member Posts: 651
    edited February 2016

    Some new developments in CD47 Immunotherapies.

    1. A new company was launched to exploit the ubiquitous over-expression of CD47 in cancer.
    The company, Forty Seven, Inc. (clever name) will license the CD47 intellectual property (IP) from Stanford.
    That increases the number of entities focused on this Immunoptherapy to eight.

    2. More CD47 research Abstracts were recently published on Pubmed.com
    NCI and NIH scientists authored the following TNBC research called: "A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer".
    This group is working with Maryland-based Paradigm Shift Therapeutics to bring Anti-CD47 therapies (PSTx-23) to metastatic breast cancer patients. I believe they are still at the pre-clinical phase.

    3. Finally, it was recently reported by CureSearch, a pediatric cancer group, that the Stanford Phase 1 clinical trial is due to be completed in early 2016. If the current studies are successful, they will be able to test CD47 targeted therapy in several different pediatric tumors.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited February 2016

    JS, Thank you once again.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited March 2016

    My wife just got diagnosed with mets. Now I am even more eager to know about the developments with CD47.

  • MusicLover
    MusicLover Member Posts: 4,225
    edited March 2016

    letmywifelive, I'm so sorry.

  • letmywifelive
    letmywifelive Member Posts: 360
    edited March 2016

    Thanks MusicLover. Today I will have further discussions with her onc in Stanford and ask about options for entering CD47 trial. By the way, do you mind telling what was the location of your mets ?

  • MusicLover
    MusicLover Member Posts: 4,225
    edited March 2016

    I was stage IV at dx, I had 2 bone mets, left and right hip area. Acetabulum and iliac. (sp?) Where did your wife's show up?

  • letmywifelive
    letmywifelive Member Posts: 360
    edited March 2016

    So far bone only - spine and pelvis. One more scan left. How's your medication working ?

  • MusicLover
    MusicLover Member Posts: 4,225
    edited March 2016

    My medication has been working well, thankfully. ( I should have said pelvis and hip). Best wishes to both of you.

  • Jumpship
    Jumpship Member Posts: 305
    edited March 2019

    Can I ask what it felt like for her? I'm dealing with bone pain? Hope she gets in the trial

  • MusicLover
    MusicLover Member Posts: 4,225
    edited March 2016

    Jumpship, It may be a good idea for you to post on Chrissyb's thread not dx with a recurrence (something like that?). I had no pain until I started the tx but I think that some people do feel pain. Best wishes to you and I hope you are cancer free.

Categories